Danish Pharmacovigilance Update, April 2011

In this issue of Danish Pharmacovigilance Update:

• Possible risk of second primary malignancies in patients treated with Revlimid® (lenalidomide)
• New contraindication for Telzir® (fosamprenavir) for HIV treatment
• New dosing recommendation for Votrient® (pazopanib) for treatment of advanced renal cell carcinoma
• New contraindication for Xyrem® (sodium oxybate) for treatment of narcolepsy
• Information about the occurrence of serious hypersensitivity reactions has been added to the summary of product characteristics of Efient® (prasugrel) for the prevention of atherothrombotic events
• Analgesic (NSAID) and risk of gastric ulcers in arthritic sufferers
• Swedish study raises suspicion about link between Pandemrix® (the H1N1 vaccine) and the sleep disorder narcolepsy in children and adolescents.
• Reports of blood clots from the use of Vivaglobin®
• Childhood vaccination and adverse reactions in 2010
• New improved e-forms for reporting suspected adverse reactions
• The Danish Medicines Agency’s annual pharmacovigilance report 2010

Download the newsletter in the box to the right.